Диссертация (Свободные и координированные ионами Pt(II), Pd(II) тетразолилуксусные кислоты как перспективные скаффолды в синтезе новых биологически активных веществ), страница 18

Popova, E.A.; Trifonov, R.E. Synthesis and biological properties of amino acidsand peptides containing a tetrazolyl moiety. Russ. Chem. Rev., 2015, 84(9), 891–916.2. Ostrovskii, V.A; Koldobskii, G.I.; Trifonov, R.E. Tetrazoles. In: ComprehensiveHeterocyclic Chemistry III, A.R. Katritzky, C.A. Ramsden, E.F.V. Scriven,R.J.K. Taylor, Ed.; Elsevier: Oxford, 2008; Vol. 6, pp. 257–424.3.

Ostrovskii, V.A.; Trifonov, R.E.; Popova, E.A. Medicinal chemistry oftetrazoles. Russ. Chem. Bull. Int. Ed., 2012, 61, 768–780.4. Herr, R. J. 5-Substituted-1H-tetrazoles as Carboxylic Acid Isosteres: MedicinalChemistry and Synthetic Methods. Bioorg. Med. Chem., 2002, 10, 3379–3393.5. Myznikov, L.V.; Hrabalek, A.; Koldobskii, G.I.

Drugs in the tetrazole series.(review). Chem. Heterocyc. Comp., 2007, 43(1), 1–9.6. Wei, Ch.-X.; Bian, M.; Gong G.-H. Tetrazolium compounds: synthesis andapplications in medicine. Molecules, 2015, 20, 5528–5553.7. Pretze, M.; Pietzsch, D.; Mamat C. Recent Trends in Bioorthogonal ClickRadiolabeling Reactions Using Fluorine-18.

Molecules, 2013, 18, 8618-8665.8. Orlovskaya, V.V.; Fedorova, O.S.; Krasikova R.N. Methods for the synthesis offluorine-18-labeled aromatic amino acids, radiotracers for positron emissiontomography (PET). Russ. Chem. Bull., 2015, 64 (7), 1518–1535.9. Trifonov, R.E.; Ostrovskii, V.A. Protolytic equilibria in tetrazoles. Russ. J.

Org.Chem., 2006, 42, 1585–1605.10.Trifonov, R.E.; Alkorta, I.; Ostrovskii, V.A.; Elguero, J. A theoretical study ofthe tautomerism and ionization of 5-substituted NH-tetrazoles. J. Mol. Struct.(Theochem.), 2004, 668, 123–132.11.Butler, R.N. In: Comprehensive Heterocyclic Chemistry II, A.R. Katritzky, C.W.Rees, E.F.V. Scriven, Ed.; Pergamon Press: New York, 1996; Vol.

4, pp. 621–678.14112.Matta, C.F.; Arabi, A.A.; Weaver D.F. The bioisosteric similarity of thetetrazole and carboxylate anions: Clues from the topologies of the electrostaticpotential and of the electron density. Eur. J. Med.Chem., 2010, 45, 1868–1872.13.Ballatore, C.; Huryn, D.M.; Smith, A.B. Carboxylic acid (bio)isosteres in drugdesign.

ChemMedChem., 2013, 8(3), 385–395.14.Allen, F.H.; Groom, C.R.; Liebeschuetz, J.W.; Bardwell, D.A.; Olsson, T.S.G.;Wood, P.A. The hydrogen bond environments of 1H-tetrazole and tetrazolaterings: the structural basis for tetrazole-carboxylic acid bioisosterism. J. Chem.Inf. Model., 2012, 52, 857–866.15.Huisgen, R. 1,3-Dipolar cycloadditions. Past and future. Angew. Chem. Int. Ed.,1963, 2(10), 565–632.16.Gaponik, P.N.; Voitekhovich, S.V.; Ivashkevich, O.A. Metal derivatives oftetrazoles.

Russ. Chem. Rev., 2006, 75(6) 507-539.17. Popova, E.A.; Trifonov, R.E.; Ostrovskii, V.A. Advances in the synthesis oftetrazoles coordinated to metal ions. ARKIVOC, 2011, 552-572.18.Johnstone, T.C.; Suntharalingam, K.; Lippard, S.J. The next generation ofplatinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV)prodrugs.

Chem. Rev., 2016, 116(5), 3436–3486.19.Huq, F.; Yu, J.Q.; Beale, Ph. In: Platinum and Other Heavy Metal Compoundsin Cancer Chemotherapy. Molecular Mechanisms and Clinical Applications;A. Bonetti, R. Leone, F.M. Muggia, S.B. Howell, Ed.; Humana Press: NewYork, 2009; Chapter: Studies on New Platinum Compounds, pp. 11–17.20.Serebryanskaya, T.V.; Yung, T.; Bogdanov, A.A.; Shchebet, A.; Johnsen, S.A.;Lyakhov, A.S.; Ivashkevich, L.S.; Ibrahimava, Z.A.; Garbuzenco, T.S.;Kolesnikova, T.S.; Melnova, N.I.; Gaponik, P.N.; Ivashkevich, O.A. Synthesis,characterization, and biological evaluation of new tetrazole-based platinum(II)and palladium(II) chlorido complexes – potent cisplatin analogues and theirtrans isomers.

J. Inorg. Biochem., 2013, 120, 44–53.21.Voitekhovich, S.V.; Serebryanskaya, T.V.; Lyakhov, A.S.; Gaponik, P.N.;Ivashkevich, O.A. Copper(II), palladium(II) and platinum(II) chloride142complexes with 5-amino-2-tert-butyltetrazole: Synthesis, characterization andcytotoxicity. Polyhedron, 2009, 28, 3614–3620.22.Bekhit, A.A.; El-Sayed, O.A.; Al-Allaf, T.A.K.; Aboul-Enein, H.Y.; Kunhi, M.,Pulicat, S.M.;Al-Hussain, K.;Al-Khodairy, F.; Arif. J. Synthesis,characterization and cytotoxicity evaluation of some new platinum(II)complexes of tetrazolo[1,5-a]quinolones. Eur. J.

Med. Chem., 2004, 39, 499–505.23.Popova, E.A.; Bokach, N.A.; Haukka, M.; Trifonov, R.E.; Ostrovskii, V.A. Anew route to N(1)-5R-tetrazole complexes via azidation to nitriles coordinated toPt(II) and Pt(IV). Inorg. Chim. Acta, 2011, 375, 242–247.24.Popova,E.A.;Serebryanskaya,T.V.;Selivanov,S.I.;Haukka,M.;Panikorovsky, T.L.; Gurzhiy, V.V.; Ott, I.; Trifonov, R.E.; Kukushkin, V.Yu.Water soluble platinum(II) complexes featuring 2-alkyl-2H-tetrazol-5-ylaceticacids: synthetic, X-ray diffraction, and solution NMR studies. Eur. J. Inorg.Chem., 2016, DOI: 10.1002/ejic.201600626.25.Komeda, S.; Lin Yuh-L.; Chikuma M. A Tetrazolato-bridged dinuclearplatinum(II) complex exhibits markedly high in vivo antitumor activity againstpancreatic cancer. Chem.

Med. Chem., 2011, 6, 987–990.26.Uemura, M.; Yoshikawa, Y.; Yoshikawa, K.; Sato, T.; Mino, Y.; Chikuma, M.;Komeda, S. Second- and higher-order structural changes of DNA induced byantitumor-active tetrazolato-bridged dinuclear platinum(II) complexes withdifferent types of 5-substituent. J. Inorg. Biochem., 2013, 127, 169–174.27.Komeda, S.; Takayama, H.; Suzuki, T.; Odani, A.; Yamori T.; Chikuma M.Synthesis of antitumor azolato-bridged dinuclear platinum(II) complexes with invivo antitumor efficacy and unique in vitro cytotoxicity profiles.

Metallomics,2013, 5, 461-468.28.Uemura, M.; Suzuki, T.; Nishio, K.; Chikuma, M.; Komeda, S. An in vivohighly antitumor-active tetrazolato-bridged dinuclear platinum(II) complexlargely circumvents in vitro cisplatin resistance: two linkage isomers yield the143same product upon reaction with 9-ethylguanine but exhibit different cytotoxicprofiles. Metallomics, 2012, 4, 686–692.29.Moreno, V.; Lorenzo, J.; Aviles, F.X.; Garcia, H.G.; Ribeiro, J.P.; Morais, T.S.;Florindo, P.; Robalo, M.P. Studies of the antiproliferative activity of ruthenium(II) cyclopentadienyl-derived complexes with nitrogen coordinated ligands.Bioinorg. Chem.

Appl., 2010, 1-12.30.Ott, I. On the medicinal chemistry of gold complexes as anticancer drugs.Coord. Chem. Rev., 2009, 253, 1670-1681.31.Nobili, S.; Mini, E.; Landini, I.; Gabbiani, C.; Casini, A.; Messori, L. Goldcompounds as anticancer agents: chemistry, cellular pharmacology, andpreclinical studies. Med. Res. Rev., 2010, 30(3), 550-580.32.Bindoli, A.; Rigobello, M.P.; Scutari, G.; Gabbiani, C.; Casini A.; Messori, L.Thioredoxin reductase: a target for gold compounds acting as potentialanticancer drugs. Coord.

Chem. Rev., 2009, 253(11), 1692–1707.33.Gandin, V.; Fernandes, A.P. Metal- and Semimetal-Containing Inhibitors ofThioredoxin Reductase as Anticancer Agents. Molecules, 2015, 20(7), 12732–12756.34.Serebryanskaya, T.V.; Lyakhov, A.S.; Ivashkevich, L.S.; Schur, J.; Frias, С.;Prokop, A.; Ott I. Gold(I) thiotetrazolates as thioredoxin reductase inhibitors andantiproliferative agents.

Dalton Trans., 2015, 44, 1161–1169.35.Wani, W.A.;Baiq, U.; Shreaz, S.; Shiekh, R.A.; Iqbal, P.F.; Jameel, E.; Ahmad,A.; Mohd-Setapar, S.H.; Mushtaque, Md.; Hun, L.T. Recent advances in ironcomplexes as potential anticancer agents. New J. Chem., 2016, 40, 1063-1090.36. Herchel, R.; Šindelář, Z.; Trávníček, Z.; Zbořil, R.; Vančo, J. Novel 1D chainFe(III)-salen-like complexes involving anionic heterocyclic N-donor ligands.Synthesis, X-ray structure, magnetic,57Fe Mössbauer, and biological activitystudies. Dalton Trans., 2009, 9870-9880.37.Vančo, J.; Šindelář Z.; Dvořák, Z.; Trávníček, Z. Iron-salophen complexesinvolving azole-derived ligands: a new group of compounds with high-level and144broad-spectrum in vitro antitumor activity.

J. Inorg. Biochem., 2015, 70, 92–100.38.Santini, C.; Pellei, M.; Gandin, V.; Porchia, M.; Tisato, F.; Marzano, C.Advances in copper complexes as anticancer agents. Chem. Rev., 2014, 114(1),815–862.39.Haleel, A.; Arthi, P.; Dastagiri Reddy, N.; Veena, V.; Sakthivel, N.; Arun, Y.;Perumal, P.T.; Kalilur Rahiman, A.

DNA binding, molecular docking andapoptotic inducing activity of nickel(II), copper(II) and zinc(II) complexes ofpyridine-based tetrazolo[1,5-a]pyrimidine ligands. RSC Adv., 2014, 4, 6081660830.40.Surendra Babu, M.S.; Umamaheswara Rao, B.; Krishna, V.; Mustafa, S.;Nageswara Rao, G. Synthesis, characterization and DNA cleavage studies ofisomeric pyridyl-tetrazole ligands and their Ni(II) and Zn(II) complexes. J.Saudi Chem. Soc., 2015, 1-9.41.Lam, K.S. New aspects of natural products in drug discovery.

TrendsMicrobiol., 2007, 15(6), 279-289.42.Cragg, G.M.; Grothaus, P.G.; Newman, D.J. Impact of Natural Products onDeveloping New Anti-Cancer Agents. Chem. Rev. 2009, 109, 3012–3043.43.Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. A.Medicinal chemistry of combretastatin A4: present and future directions. J. Med.Chem., 2006, 49, 3033−3044.44.Chaudari, A.; Pandeya, S. N.; Kumar, P.; Sharma, P. P.; Gupta, S.; Soni, N.;Verma, K. K.; Bhardwaj, G. Combretastain A-4 analogues as anticancer agents.Mini-Rev.

Med. Chem. 2007, 12, 1186−1205.45.Hsieh, H. P.; Liou, J. P.; Mahindroo, N. Pharmaceutical design of antimitoticagents based on combretastatins. Curr. Pharm. Des., 2005, 11, 1655−1677.[46] Mahindroo, N; Liou, J. P.; Chang, J. Y.; Hsieh, H. P. Antitubulin agents forthe treatment of cancer – а medicinal chemistry update.

Expert Opin. Ther. Pat.,2006, 16, 647−691.14546. Pettit, G.R.; Rhodes, M.R.; Herald, D.; Hamel, E.; Schmidt, J.M.; Pettit, R.K.Antineoplastic agents. 445. Synthesis and evaluation of structural modificationsof (Z)- and (E)-combretastatin A-41. J Med Chem., 2005, 48, 4087–4099.47.Nathwani, S.-M.; Hughes, L.; Greene, L.M.; Carr, M.; O'Boyle, N.M.;McDonnell, S.; Meegan, M.J.; Zisterer, D.M.

Novel cis-restricted β-lactamcombretastatin A-4 analogues display anti-vascular and anti-metastaticproperties in vitro. Oncology reports, 2013, 29, 585–594.48.Wang L., Woods K. W., Li Q., Barr K. J., McCroskey R. W., Hannick S. M.,Gherke L., Credo R. B., Hui Y.-H., Marsh K., Warner R., Lee J. Y., ZielinskiMozng N., Frost D., Rosenberg S. H., Sham H. L. Potent, orally activeheterocycle-based combretastatin A-4 analogues: synthesis, structure-activityrelationship, pharmacokinetics, and in vivo antitumor activity evaluation. J.Med.

Chem., 2002, 45, 1697–1711.49. Zhang, Q.; Peng, Y.; Wang, X.Y.; Keenan, S.M.; Arora, S.; Welsh, W.J. HighlyPotent Triazole-Based Tubulin Polymerization Inhibitors. J Med Chem., 2007,50(4), 749–754.50. Romagnoli, R.; Baraldi, P.G.; Salvador, M.K.; Preti, D.; Tabrizi, M.A.;Brancale, A.; Fu, X.-H.; Li, J.; Zhang, S.-Z.; Hamel, E.; Bortolozzi, R.; Basso,G.; Viola, G.